{"type":"trials","record":{"id":128,"source_id":"clinicaltrials-gov","external_id":"NCT03861767","title":"REMAP Trial for Optimizing Surgical Outcomes at UPMC","brief_summary":"The purpose of this project is to determine the effect of various interventions to improve patient outcome as defined by hospital free days at day 90 for adult patients undergoing elective surgery. Within this project, multiple studies may be conducted. The structure of this project permits: * the testing of multiple treatments at the same time within the same patient * the use of early study results to provide better treatment options to future patients * the removal of treatments which are shown to be less effective than the other treatments * the addition of new treatments The first study to be conducted under this project (IRB STUDY19090186) is the Strategies to Promote ResiliencY (SPRY) clinical trial (IRB PRO18060038). The SPRY clinical trial will determine the effectiveness of Metformin on improving surgical outcomes among nondiabetic older adults who are scheduled for elective surgery.","overall_status":"Terminated","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Matthew Neal MD","enrollment":302,"countries":["United States"],"start_date":"2019-04-15","completion_date":"2022-09-23","last_update_date":"2024-06-18","source_url":"https://clinicaltrials.gov/study/NCT03861767","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:45:00.13201+00:00","last_seen_at":"2026-09-25T06:00:18.815+00:00","metadata":{"sex":"ALL","acronym":"UPMCREMAP","age_range":"18 Years","comparator":"SPRY: Placebo","organization":"University of Pittsburgh","interventions":["Metformin ER","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Hospital Free Days (HFD) — Day 90 from the date of the elective surgical procedure","Incidence of ICU Admission After Surgery — Participants will be followed for the duration of their hospital admission,…","Incidence and Total Number of Reoperation/Reintervention — Day 90 from the date of the elective surgical procedure","Venous Thromboembolic Events Including Deep Vein Thrombosis and Pulmonary Embolism — Day 90 from the date of the electi…","Number of Participants With Surgical Site Infection — Day 30 from the date of the elective surgical procedure","Number of Participants With Surgical Site Occurrence — Day 30 from the date of the elective surgical procedure","Organ Failure Free Days — Day 30 from the date of the elective surgical procedure","Hospital Length of Stay (LOS) — Participants will be followed for the duration of their hospital admission, estimated t…","ICU (Intensive Care Unit) Length of Stay (LOS) — Participants will be followed for the duration of their hospital admis…","Mortality — Day 90 from the date of the elective surgical procedure","Hospital Readmission Rate — Day 90 from the date of the elective surgical procedure","Gastrointestinal Intolerance — From enrollment to day 90 after surgery","SAE (Serious Adverse Event) as Defined in Core Protocol (Mild, Moderate, Severe, Life Threatening/Disabling; Adjudicate…","Discharge Disposition — Participants will be followed for the duration of their hospital admission, estimated to be 2-4…","In Hospital Mortality — Participants will be followed for the duration of their hospital admission, estimated to be 2-4…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":true},"controlled_terms":["Aging","Metformin ER","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: metformin.","quality_checked_at":"2026-09-25T06:00:19.43954+00:00","duplicate_cluster_key":"id:nct03861767","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-04-15 to 2022-09-23","comparator":"SPRY: Placebo","confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:00:18.821Z","intervention":["Metformin ER","Placebo"],"participants":302,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Hospital Free Days (HFD) — Day 90 from the date of the elective surgical procedure","Incidence of ICU Admission After Surgery — Participants will be followed for the duration of their hospital admission,…","Incidence and Total Number of Reoperation/Reintervention — Day 90 from the date of the elective surgical procedure","Venous Thromboembolic Events Including Deep Vein Thrombosis and Pulmonary Embolism — Day 90 from the date of the electi…","Number of Participants With Surgical Site Infection — Day 30 from the date of the elective surgical procedure","Number of Participants With Surgical Site Occurrence — Day 30 from the date of the elective surgical procedure","Organ Failure Free Days — Day 30 from the date of the elective surgical procedure","Hospital Length of Stay (LOS) — Participants will be followed for the duration of their hospital admission, estimated t…","ICU (Intensive Care Unit) Length of Stay (LOS) — Participants will be followed for the duration of their hospital admis…","Mortality — Day 90 from the date of the elective surgical procedure","Hospital Readmission Rate — Day 90 from the date of the elective surgical procedure","Gastrointestinal Intolerance — From enrollment to day 90 after surgery","SAE (Serious Adverse Event) as Defined in Core Protocol (Mild, Moderate, Severe, Life Threatening/Disabling; Adjudicate…","Discharge Disposition — Participants will be followed for the duration of their hospital admission, estimated to be 2-4…","In Hospital Mortality — Participants will be followed for the duration of their hospital admission, estimated to be 2-4…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"metformin","is_published":true,"match_reasons":["Abstract contains controlled term: metformin.","Source terminology contains: metformin.","Abstract supplies longevity context: older adult.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Metformin","slug":"metformin"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/128","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}